RXRX Today - Aug 09: Mixed Q2 Results Reaction

カートのアイテムが多すぎます

ご購入は五十タイトルがカートに入っている場合のみです。

カートに追加できませんでした。

しばらく経ってから再度お試しください。

ウィッシュリストに追加できませんでした。

しばらく経ってから再度お試しください。

ほしい物リストの削除に失敗しました。

しばらく経ってから再度お試しください。

ポッドキャストのフォローに失敗しました

ポッドキャストのフォロー解除に失敗しました

RXRX Today - Aug 09: Mixed Q2 Results Reaction

無料で聴く

ポッドキャストの詳細を見る

Hey, what's up? It’s Joey here, your friendly longtime investor. Today, we’re talking about Recursion Pharmaceuticals, or RXRX. It had a red day, down about 1.26%.

So, here’s the scoop. RXRX opened a bit shaky and just kinda trailed off. It was hanging around the same spot for most of the day, but it did get a little boost earlier when news dropped about their Q2 results. They reported a narrower net loss, which is kinda good, but overall, the revenue pressure seems to be weighing on folks’ minds.

Now, why the mixed reactions? Well, people were stoked about the narrower loss – you know, less bad news is still good news – but then they looked closer and saw revenue wasn’t exactly crushing it. So, it’s like a double-edged sword. Some investors hit the sell button fast, probably worried about future earnings. Plus, there was some insider selling going on. Their director Blake Borgeson sold off nearly $100,000 in stock. That usually raises some eyebrows, right?

And just to keep it real, there’s always some uncertainty with stocks like this. Nobody really knows if that insider selling is a red flag or just a regular thing.

One thing to keep an eye on is the upcoming news about AbCellera. Their shares are surging ahead of some major trial results on Monday. That might shake up the biotech space a bit, and who knows, it could impact RXRX too since they’re all in that same industry.

Alright, that’s the lowdown for today. Just remember, I’m here to keep you informed and entertained, not to give financial advice. Stay savvy, my friend!

まだレビューはありません